Unravelling the flexibility of Mycobacterium tuberculosis: an escape way for the bacilli.

The persistence of Mycobacterium tuberculosis makes it difficult to eradicate the associated infection from the host. The flexible nature of mycobacteria and their ability to adapt to adverse host conditions give rise to different drug-tolerant phenotypes. Granuloma formation restricts nutrient supply, limits oxygen availability and exposes bacteria to a low pH environment, resulting in non-replicating bacteria. These non-replicating mycobacteria, which need high doses and long exposure to anti-tubercular drugs, are the root cause of lengthy chemotherapy. Novel strategies, which are effective against non-replicating mycobacteria, need to be adopted to shorten tuberculosis treatment. This not only will reduce the treatment time but also will help prevent the emergence of multi-drug-resistant strains of mycobacteria.

[1]  Vishvanath Tiwari,et al.  Anti-persister strategies against stress induced bacterial persistence. , 2022, Microbial pathogenesis.

[2]  R. Chikhale,et al.  Challenges in Targeting Mycobacterial ATP Synthase: The Known and Beyond , 2022 .

[3]  Samreen Fatima,et al.  Advances in adjunct therapy against tuberculosis: Deciphering the emerging role of phytochemicals , 2021, MedComm.

[4]  K. Rhee,et al.  Growth of Mycobacterium tuberculosis at acidic pH depends on lipid assimilation and is accompanied by reduced GAPDH activity , 2021, Proceedings of the National Academy of Sciences.

[5]  V. Nandicoori,et al.  Redox homeostasis in Mycobacterium tuberculosis is modulated by a novel actinomycete‐specific transcription factor , 2021, The EMBO journal.

[6]  W. Denny Inhibitors of F1F0ATP synthase enzymes for the treatment of tuberculosis and cancer. , 2021, Future medicinal chemistry.

[7]  X. Guan,et al.  Metabolic Versatility of Mycobacterium tuberculosis during Infection and Dormancy , 2021, Metabolites.

[8]  J. Rubinstein,et al.  Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline , 2020, Nature.

[9]  C. Nathan,et al.  Biology of antimicrobial resistance and approaches to combat it , 2020, Science Translational Medicine.

[10]  L. Tsenova,et al.  Effects of host‐directed therapies on the pathology of tuberculosis , 2020, The Journal of pathology.

[11]  N. Chandel,et al.  Mitochondrial TCA cycle metabolites control physiology and disease , 2020, Nature Communications.

[12]  P. Nahid,et al.  The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials , 2019, PLoS medicine.

[13]  R. Nair,et al.  Mycobacterium smegmatis moxifloxacin persister cells produce high levels of hydroxyl radical, generating genetic resisters selectable not only with moxifloxacin, but also with ethambutol and isoniazid. , 2019, Microbiology.

[14]  Charles L. Dulberger,et al.  The mycobacterial cell envelope — a moving target , 2019, Nature Reviews Microbiology.

[15]  R. B. Abramovitch,et al.  Acid Fasting: Modulation of Mycobacterium tuberculosis Metabolism at Acidic pH. , 2019, Trends in microbiology.

[16]  Kishor Jakkala,et al.  Hypoxic Non-replicating Persistent Mycobacterium tuberculosis Develops Thickened Outer Layer That Helps in Restricting Rifampicin Entry , 2019, Front. Microbiol..

[17]  C. Vilchèze,et al.  The Isoniazid Paradigm of Killing, Resistance, and Persistence in Mycobacterium tuberculosis. , 2019, Journal of molecular biology.

[18]  Sang-Nae Cho,et al.  Transient drug-tolerance and permanent drug-resistance rely on the trehalose-catalytic shift in Mycobacterium tuberculosis , 2019, Nature Communications.

[19]  Naveed Sabir,et al.  Nilotinib: A Tyrosine Kinase Inhibitor Mediates Resistance to Intracellular Mycobacterium Via Regulating Autophagy , 2019, Cells.

[20]  T. Parish,et al.  The relevance of persisters in tuberculosis drug discovery. , 2019, Microbiology.

[21]  J. Collins,et al.  Publisher Correction: Definitions and guidelines for research on antibiotic persistence , 2019, Nature Reviews Microbiology.

[22]  Alimuddin Zumla,et al.  The changing treatment landscape for MDR/XDR-TB - Can current clinical trials revolutionise and inform a brave new world? , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[23]  Arun Sharma,et al.  Mycobacterium tuberculosis Rv0366c-Rv0367c encodes a non-canonical PezAT-like toxin-antitoxin pair , 2019, Scientific Reports.

[24]  S. Hasnain,et al.  Mycobacterium Tuberculosis: Molecular Infection Biology, Pathogenesis, Diagnostics and New Interventions , 2019 .

[25]  Prabhakar Tiwari,et al.  Structural, functional and biological insights into the role of Mycobacterium tuberculosis VapBC11 toxin–antitoxin system: targeting a tRNase to tackle mycobacterial adaptation , 2018, Nucleic acids research.

[26]  T. Tuller,et al.  Genome-wide analysis of horizontally acquired genes in the genus Mycobacterium , 2018, Scientific Reports.

[27]  R. Slayden,et al.  Toxin-antitoxin systems and regulatory mechanisms in Mycobacterium tuberculosis. , 2018, Pathogens and disease.

[28]  M. Fauvart,et al.  Fighting bacterial persistence: Current and emerging anti-persister strategies and therapeutics. , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[29]  Bryan D. Bryson,et al.  Posttranslational modification of a histone-like protein regulates phenotypic resistance to isoniazid in mycobacteria , 2018, Science Advances.

[30]  D. Schnappinger,et al.  Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis , 2018, Nature Reviews Microbiology.

[31]  Naveed Sabir,et al.  miRNAs in Tuberculosis: New Avenues for Diagnosis and Host-Directed Therapy , 2018, Front. Microbiol..

[32]  J. Collins,et al.  Targeting Antibiotic Tolerance, Pathogen by Pathogen , 2018, Cell.

[33]  D. Hung,et al.  The Expanding Diversity of Mycobacterium tuberculosis Drug Targets. , 2018, ACS infectious diseases.

[34]  Shweta Sharma,et al.  Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality? , 2017, Infectious diseases.

[35]  Sumit Sharma,et al.  Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis. , 2018, Tuberculosis.

[36]  N. Dillon,et al.  Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA , 2017, Scientific Reports.

[37]  Madavan Vasudevan,et al.  Co-expression network analysis of toxin-antitoxin loci in Mycobacterium tuberculosis reveals key modulators of cellular stress , 2017, Scientific Reports.

[38]  J. Sperry,et al.  Targeting isocitrate lyase for the treatment of latent tuberculosis. , 2017, Drug discovery today.

[39]  M. Berney,et al.  Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection , 2017, Proceedings of the National Academy of Sciences.

[40]  E. Rubin,et al.  Deletion of a mycobacterial divisome factor collapses single-cell phenotypic heterogeneity , 2017, Nature.

[41]  D. Moody,et al.  Metabolic anticipation in Mycobacterium tuberculosis , 2017, Nature Microbiology.

[42]  R. Fisher,et al.  Persistent bacterial infections and persister cells , 2017, Nature Reviews Microbiology.

[43]  B. Görke,et al.  Roles of Regulatory RNAs for Antibiotic Resistance in Bacteria and Their Potential Value as Novel Drug Targets , 2017, Front. Microbiol..

[44]  D. Ramos,et al.  Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis , 2017, Front. Microbiol..

[45]  Joel S. Freundlich,et al.  Enhanced respiration prevents drug tolerance and drug resistance in Mycobacterium tuberculosis , 2017, Proceedings of the National Academy of Sciences.

[46]  T. Parish,et al.  Antituberculosis drugs: reducing efflux=increasing activity. , 2017, Drug discovery today.

[47]  P. Kirchhoff,et al.  Inhibitors of Mycobacterium tuberculosis DosRST signaling and persistence. , 2017, Nature chemical biology.

[48]  Yoonji Kim,et al.  Functional Studies of Five Toxin-Antitoxin Modules in Mycobacterium tuberculosis H37Rv , 2016, Front. Microbiol..

[49]  A. Steyn,et al.  Turning the respiratory flexibility of Mycobacterium tuberculosis against itself , 2016, Nature Communications.

[50]  K. Lewis,et al.  High Persister Mutants in Mycobacterium tuberculosis , 2016, PloS one.

[51]  Liem Nguyen Antibiotic resistance mechanisms in M. tuberculosis: an update , 2016, Archives of Toxicology.

[52]  Ofer Fridman,et al.  Distinguishing between resistance, tolerance and persistence to antibiotic treatment , 2016, Nature Reviews Microbiology.

[53]  Vikram Saini,et al.  Ergothioneine Maintains Redox and Bioenergetic Homeostasis Essential for Drug Susceptibility and Virulence of Mycobacterium tuberculosis. , 2016, Cell reports.

[54]  A. Chaudhury,et al.  HIV-Associated TB Syndemic: A Growing Clinical Challenge Worldwide , 2015, Front. Public Health.

[55]  G. Schoolnik,et al.  Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis. , 2015, The Journal of infectious diseases.

[56]  D. Schnappinger,et al.  Disruption of an M. tuberculosis Membrane Protein Causes a Magnesium-dependent Cell Division Defect and Failure to Persist in Mice , 2015, PLoS pathogens.

[57]  Benjamin K. Johnson,et al.  Slow growth of Mycobacterium tuberculosis at acidic pH is regulated by phoPR and host‐associated carbon sources , 2014, Molecular microbiology.

[58]  E. Rubin,et al.  How sisters grow apart: mycobacterial growth and division , 2014, Nature Reviews Microbiology.

[59]  W. Jacobs,et al.  Molecular Genetics of Mycobacteria, Second Edition , 2014 .

[60]  Se Yeon Kim,et al.  Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis , 2013, Nature Medicine.

[61]  C. Nathan,et al.  Whole Cell Screen for Inhibitors of pH Homeostasis in Mycobacterium tuberculosis , 2013, PloS one.

[62]  C. Vilchèze,et al.  Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction , 2013, Nature Communications.

[63]  K. Rhee,et al.  Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis , 2013, Proceedings of the National Academy of Sciences.

[64]  A. Cataldi,et al.  Virulence factors of the Mycobacterium tuberculosis complex , 2013, Virulence.

[65]  Carl Nathan,et al.  Fresh Approaches to Anti-Infective Therapies , 2012, Science Translational Medicine.

[66]  J. Collins,et al.  Heterogeneous Bacterial Persisters and Engineering Approaches to Eliminate Them This Review Comes from a Themed Issue on Genomics Edited More than One Way to Make a Persister Persisters and Physiological Heterogeneity Engineering Treatments for Persisters , 2022 .

[67]  Ying Zhang,et al.  Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis , 2011, Science.

[68]  C. Sassetti,et al.  Metabolic Regulation of Mycobacterial Growth and Antibiotic Sensitivity , 2011, PLoS biology.

[69]  Eric Arnoult,et al.  The challenge of new drug discovery for tuberculosis , 2011, Nature.

[70]  A. Velayati,et al.  Sequential adaptation in latent tuberculosis bacilli: observation by atomic force microscopy (AFM). , 2011, International journal of clinical and experimental medicine.

[71]  N. Singhal,et al.  Streptomycin induced protein expression analysis in Mycobacterium tuberculosis by two-dimensional gel electrophoresis & mass spectrometry. , 2010, The Indian journal of medical research.

[72]  J. Flynn,et al.  The spectrum of latent tuberculosis: rethinking the biology and intervention strategies , 2009, Nature Reviews Microbiology.

[73]  W. Bishai,et al.  Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. , 2009, The Journal of infectious diseases.

[74]  Thomas Dick,et al.  The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis , 2008, Proceedings of the National Academy of Sciences.

[75]  C. Senner,et al.  Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum , 2008, PLoS medicine.

[76]  W. Hillen,et al.  In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice , 2007, Nature Medicine.

[77]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[78]  H. Engelhardt,et al.  The MspA porin promotes growth and increases antibiotic susceptibility of both Mycobacterium bovis BCG and Mycobacterium tuberculosis. , 2004, Microbiology.

[79]  James C. Sacchettini,et al.  Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase , 2000, Nature.

[80]  L. Wayne,et al.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence , 1996, Infection and immunity.

[81]  G. Hobby,et al.  Observations on the Mechanism of Action of Penicillin.∗ , 1942 .